234 related articles for article (PubMed ID: 25555447)
1. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.
Costa LJ; Huang JX; Hari PN
Biol Blood Marrow Transplant; 2015 Apr; 21(4):701-6. PubMed ID: 25555447
[TBL] [Abstract][Full Text] [Related]
2. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.
Schriber JR; Hari PN; Ahn KW; Fei M; Costa LJ; Kharfan-Dabaja MA; Angel-Diaz M; Gale RP; Ganguly S; Girnius SK; Hashmi S; Pawarode A; Vesole DH; Wiernik PH; Wirk BM; Marks DI; Nishihori T; Olsson RF; Usmani SZ; Mark TM; Nieto YL; D'Souza A
Cancer; 2017 Aug; 123(16):3141-3149. PubMed ID: 28472539
[TBL] [Abstract][Full Text] [Related]
3. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.
Auner HW; Szydlo R; Hoek J; Goldschmidt H; Stoppa AM; Morgan GJ; Moreau P; Attal M; Marit G; Russell N; Brune M; Cook G; Sonneveld P; Schönland S; Garderet L; Kröger N
Bone Marrow Transplant; 2015 Feb; 50(2):209-15. PubMed ID: 25387088
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
Munshi PN; Vesole DH; St Martin A; Davila O; Kumar S; Qazilbash M; Shah N; Hari PN; D'Souza A
Cancer; 2021 Nov; 127(22):4233-4239. PubMed ID: 34374445
[TBL] [Abstract][Full Text] [Related]
5. Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities.
Ailawadhi S; Adu Y; Frank RD; Das S; Hodge DO; Fernandez A; Flott C; Elliott J; Parrondo R; Sher T; Roy V; Chanan-Khan AA
Blood Cancer J; 2024 May; 14(1):86. PubMed ID: 38806475
[TBL] [Abstract][Full Text] [Related]
6. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.
Auner HW; Garderet L; Kröger N
Br J Haematol; 2015 Nov; 171(4):453-62. PubMed ID: 26213240
[TBL] [Abstract][Full Text] [Related]
7. Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database.
Liu Y; Han H; Shah G; Giralt S; Ola Landgren C; He J; Lesokhin AM
Biol Blood Marrow Transplant; 2019 Jan; 25(1):41-46. PubMed ID: 30195073
[TBL] [Abstract][Full Text] [Related]
8. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents.
Al-Hamadani M; Hashmi SK; Go RS
Am J Hematol; 2014 Aug; 89(8):825-30. PubMed ID: 24799343
[TBL] [Abstract][Full Text] [Related]
9. Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma.
Fiala MA; Finney JD; Stockerl-Goldstein KE; Tomasson MH; DiPersio JF; Vij R; Wildes TM
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1153-4. PubMed ID: 25771403
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients.
Jandial A; Lad D; Jain A; Khadwal A; Singh C; Prakash G; Suri V; Sreedharanunni S; Sachdeva MUS; Ray P; Varma N; Varma S; Malhotra P
Transpl Infect Dis; 2023 Oct; 25(5):e14123. PubMed ID: 37573150
[TBL] [Abstract][Full Text] [Related]
11. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.
Hari PN; Majhail NS; Zhang MJ; Hassebroek A; Siddiqui F; Ballen K; Bashey A; Bird J; Freytes CO; Gibson J; Hale G; Holmberg L; Kamble R; Kyle RA; Lazarus HM; LeMaistre CF; Loberiza F; Maiolino A; McCarthy PL; Milone G; Omondi N; Reece DE; Seftel M; Trigg M; Vesole D; Weiss B; Wiernik P; Lee SJ; Rizzo JD; Mehta P
Biol Blood Marrow Transplant; 2010 Mar; 16(3):395-402. PubMed ID: 19922808
[TBL] [Abstract][Full Text] [Related]
12. Second primary malignancy after multiple myeloma-population trends and cause-specific mortality.
Costa LJ; Godby KN; Chhabra S; Cornell RF; Hari P; Bhatia S
Br J Haematol; 2018 Aug; 182(4):513-520. PubMed ID: 29974936
[TBL] [Abstract][Full Text] [Related]
13. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.
Mahindra A; Hari P; Fraser R; Fei M; Huang J; Berdeja J; Callander N; Costa L; Diaz MA; Freytes C; Gale RP; Girnius S; Holmberg L; Kharfan-Dabaja M; Kumar S; Kyle R; Lazarus H; Lee C; Maiolino A; Moreb J; Nishihori T; Pawarode A; Saad A; Savani BN; Schriber J; William B; Wirk BM; Krishnan A; Nieto Y; D'Souza A
Bone Marrow Transplant; 2017 Dec; 52(12):1616-1622. PubMed ID: 28920949
[TBL] [Abstract][Full Text] [Related]
14. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
Hong S; Rybicki L; Abounader D; Bolwell BJ; Dean R; Gerds AT; Hamilton BK; Hill BT; Jagadeesh D; Kalaycio M; Liu HD; Pohlman B; Sobecks R; Majhail NS
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1141-1144. PubMed ID: 26995694
[TBL] [Abstract][Full Text] [Related]
15. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.
Kumar SK; Dispenzieri A; Fraser R; Mingwei F; Akpek G; Cornell R; Kharfan-Dabaja M; Freytes C; Hashmi S; Hildebrandt G; Holmberg L; Kyle R; Lazarus H; Lee C; Mikhael J; Nishihori T; Tay J; Usmani S; Vesole D; Vij R; Wirk B; Krishnan A; Gasparetto C; Mark T; Nieto Y; Hari P; D'Souza A
Leukemia; 2018 Apr; 32(4):986-995. PubMed ID: 29263438
[TBL] [Abstract][Full Text] [Related]
16. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Kumar A; Kharfan-Dabaja MA; Glasmacher A; Djulbegovic B
J Natl Cancer Inst; 2009 Jan; 101(2):100-6. PubMed ID: 19141779
[TBL] [Abstract][Full Text] [Related]
17. Older patients with myeloma derive similar benefit from autologous transplantation.
Sharma M; Zhang MJ; Zhong X; Abidi MH; Akpek G; Bacher U; Callander NS; Dispenzieri A; Freytes CO; Fung HC; Gale RP; Gasparetto C; Gibson J; Holmberg LA; Kindwall-Keller TL; Klumpp TR; Krishnan AY; Landau HJ; Lazarus HM; Lonial S; Maiolino A; Marks DI; Mehta P; Mikhael Med JR; Nishihori T; Olsson R; Ramanathan M; Roy V; Savani BN; Schouten HC; Scott E; Tay J; To LB; Vesole DH; Vogl DT; Hari P
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1796-803. PubMed ID: 25046833
[TBL] [Abstract][Full Text] [Related]
18. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
[TBL] [Abstract][Full Text] [Related]
19. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
[TBL] [Abstract][Full Text] [Related]
20. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
